uniQure (QURE) Surges 76.5%: Is This an Indication of Further Gains?

This human gene therapy company is expected to post quarterly loss of $1.24 per share in its upcoming report, which represents a year-over-year change of +13.9%. Revenues are expected to be$ 3.47 million, up 43.2% from the year-ago quarter. Adaptive Biotechnologies' consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.32. Compared to the company's year-ago EPS, this represents a change of +3%. Adaptive Biotechnologies currently boasts a Zacks Rank of #2 (Buy). For ...